ImageneBio, Inc. (IMA) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$6.9M

EPS$-9.64

Market Cap$51.1M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Kristin Yarema

CEO & Executive Director

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Founded: 2019
Employees: 15
Headquarters: San Diego, California, United States
Website

⚡

Core Efficiency

ROE?

-5.19%

ROA?

-4.52%

D/E Ratio?

0.15

📊

Profitability Ratios

Current Ratio?

12.49

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

May 30, 2026 (in 51 days)

Annual Report (10-K) — Based on filing pattern

May 30, 2026

Predicted10-K

Mar 10, 2026

10-KQ4 202569d after period end

Nov 12, 2025

10-QQ3 20259d after period end

Jul 24, 2025

10-QQ2 202524d after period end

May 8, 2025

10-QQ1 20257d after period end

Mar 6, 2025

10-KQ4 20246d after period end

Nov 7, 2024

10-QQ3 20246d after period end

Aug 8, 2024

10-QQ2 20247d after period end

May 13, 2024

10-QQ1 202412d after period end

Loading company sections...

ImageneBio, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness